Join us for a webinar with Vera Therapeutics, featuring Richard Lafayette, M.D., F.A.C.P. (Stanford University Medical Center), discussing the week 36 data from the Phase 2b ORIGIN clinical trial of atacicept for the treatment of IgA nephropathy (IgAN), which are initially being presented as a late-breaking clinical trial at the 60th European Renal Association (ERA) Congress on June 17, 2023.

Atacicept is a potential best-in-class, disease-modifying dual inhibitor of the cytokines B lymphocyte stimulator (BLyS) and a proliferation inducing ligand (APRIL).

A live question and answer session will follow the formal presentation.